Allergy-Immunology Department, Walter Reed
Army Medical Center, Washington, D.C.,1 and
Department of Microbiology, Colorado State University, Fort
Collins, Colorado2
Received 7 August 2000/Returned for modification 19 October
2000/Accepted 8 December 2000
Although delayed-type hypersensitivity skin testing with tuberculin
purified protein derivative (PPD) is the standard for tuberculosis
screening, its variability suggests the need for a more sensitive,
noninvasive test. An in vitro whole-blood assay has been proposed as an
alternative. Using health care worker volunteers, we confirmed the
correlation between PPD skin test (PPD-ST) results (positive,
induration of >15 mm) and a standardized gamma interferon (IFN-
)
assay, QuantiFERON-TB (Q-IFN), manufactured by CSL Biosciences in
Australia, and we evaluated Mycobacterium tuberculosis
culture subfractions as potential substitutes for PPD. Twenty healthy
volunteers with positive PPD-ST results and 20 PPD-ST-negative controls
were enrolled. Whole blood was cultured with human PPD antigens
(HuPPD), Mycobacterium avium complex (MAC) PPD,
phytohemagglutinin (PHA), and four M. tuberculosis culture subfractions: low-molecular-weight culture, filtrate, culture filtrate
without lipoarabinomannan, soluble cell wall proteins, and cytosolic
proteins, all developed from M. tuberculosis strain H37RV. Secretion of IFN-
(expressed as international
units per milliliter) was measured by an enzyme immunoassay. The PPD or subculture fraction response as a percentage of the PHA response was
used to determine positivity. Sixteen of 20 PPD-ST-positive individuals
were classified as M. tuberculosis positive by Q-IFN, and 1 was classified as MAC positive. Sixteen of 20 PPD-ST-negative individuals were M. tuberculosis negative by Q-IFN, 2 were
MAC positive, and 2 were M. tuberculosis positive. The
tuberculosis culture subfractions stimulated IFN-
production in
PPD-ST-positive volunteers, and significant differences could be seen
between the two PPD-ST groups with all subfractions except soluble cell wall protein; however, the response was variable and no better than the
Q-IFN PPD. The agreement between the Q-IFN test and the PPD-ST was good
(Cohen's kappa = 0.73). The Q-IFN assay can be a useful tool in
further studies of immune responses to M. tuberculosis antigens.
 |
INTRODUCTION |
The immune response to mycobacterial
infection is predominantly cellular (5). Delayed-type
hypersensitivity (DTH) skin testing has been a convenient,
cost-effective method for assessing cell-mediated immune responses to a
variety of antigens, starting with the mycobacterium-derived tuberculin
purified protein derivative (PPD) over 100 years ago (28).
Also known as the Mantoux test, this method has been the "gold
standard" for diagnostic screening for detection of new or
asymptomatic Mycobacterium tuberculosis infections. Although
the test is reasonably priced, there continue to be multiple factors
challenging the accuracy of the PPD skin test (PPD-ST) in different
settings. These factors include (but are not limited to) special
nursing skill requirements for placement and reading, variability in
operator placement and reading, cross-reactivity among mycobacterial
species (including M. avium and M. bovis BCG), the need for the patient to return in 48 to 72 h for a reading, and the modulation of the skin response due to underlying illness or
immunosuppression (6, 28). Although the specificity of a
significant positive test exceeds 95% in cattle, the sensitivity of
the test in both animals and humans may be less than 75% (11, 31).
The immune response to M. tuberculosis is highly dependent
upon gamma interferon (IFN-
) production by macrophages and
antigen-specific T cells (9). Over the past decade, there
has been an increasing interest in the development and application of
in vitro culture assays measuring IFN-
production in response to
tuberculin antigen stimulation as diagnostic screening tests
substituting for the classic PPD (19). Although it
initially used peripheral blood mononuclear cells (PBMC), the
methodology evolved to a whole-blood culture technique that was first
validated in Australian cattle (24, 31). The whole-blood
culture technique requires less incubation time, is technically
simpler, and provides a milieu closer to in vivo conditions. A
standardized diagnostic kit with a specifically defined data analysis
procedure, using human PPD, avian PPD, and the mitogen
phytohemagglutinin (PHA), has been marketed by CDL Limited in Australia
(QuantiFERON-TB or Q-IFN).
The purpose of this study is twofold: first, to assess the agreement
between the Q-IFN assay and the Mantoux skin test (PPD) in classically
PPD positive and PPD negative healthy volunteers; second, to evaluate
five separate fractional extracts derived from M. tuberculosis cultures in the same Q-IFN assay system and determine
concordance with the PPD-ST results.
 |
MATERIALS AND METHODS |
Participants and skin testing.
Forty-eight volunteers, all
hospital employees, were recruited from the immunization clinic of a
tertiary-care hospital in Washington, D.C. The ages of the participants
ranged from 25 to 56 years, with a median age of 35. Prior to
enrollment, all subjects were skin tested with 0.1 ml of 5-TU
(tuberculin units) PPD placed intradermally according to the standard
technique (Mantoux technique) (20). Depressed cellular
immunity from any cause was ruled out using a panel of recall antigens
that define the presence or absence of clinical anergy
(13). The antigen panel included aqueous tetanus toxoid
(1.6 Lf (limit of flocculation)/ml; Pasteur-Merieux-Connaught, Swiftwater, Pa.), candida (1:100; Hollister-Steir, Spokane, Wash.), and
mumps (40 CFU/ml; Pasteur-Merieux-Connaught). Twenty of 28 subjects
with a prior history of PPD-ST positivity (PPD-POS) were reproducibly
positive at the time of enrollment. The eight with a positive history
who tested PPD-ST negative at the time of enrollment were treated as a
separate group (Prior-POS). None of these 28 patients had any prior
history of BCG vaccination. The PPD-POS subjects were age and gender
matched with 20 subjects who had both negative histories and negative
PPD-ST results (PPD-NEG) at enrollment. All PPD-STs were placed and
read by a certified nurse who performs these duties regularly. All
readings were performed with the palpation and ballpoint methods along
two axes of the forearm (J. E. Sokal, Editorial, N. Engl.
J. Med. 293:501-502, 1975). A positive reading was
defined as induration greater than 15 mm in diameter. None of the
subjects had any known history of exposure, and all PPD-POS individuals
had negative chest X-rays with normal complete blood counts and liver
function tests. Informed consent was obtained from all subjects, and
the study was approved by the local institutional review board.
Whole-blood culture.
Venous blood was collected from the
participants in sodium heparinized tubes prior to intradermal skin
testing. Whole-blood culture was performed by aliquoting 1 ml of blood
in wells of a 24-well tissue culture plate (Costar) within 2 h
after collection. The whole blood was stimulated with either sterile
phosphate-buffered saline (Nil control antigen; 3 drops according to
the Q-IFN kit instructions), a mitogen (positive control; PHA [3
drops]), human PPD (HuPPD; 3 drops), avian PPD (AvPPD; 3 drops), or an
optimal concentration of a tuberculosis-specific antigen as described below. The tissue culture plates were incubated for 18 to 20 h (37°C,
5% CO2 2-95% air, 100% humidity). Plasma was harvested and stored
for later quantification of IFN-
by an enzyme immunoassay (EIA)
provided with the Q-IFN kit.
Tuberculosis-specific antigens.
The subfractions were
prepared in the Mycobacteria Research Laboratories, Department of
Microbiology, Colorado State University. The following subcellular
fractions of M. tuberculosis were studied in the whole blood
assay: 1- to 10-kDa low-molecular-weight culture filtrate proteins
(LMWCFP), whole culture filtrate proteins without lipoarabinomannan
(CFP-LAM), soluble cell wall proteins (SCWP), cytosolic proteins (CYT),
and M. tuberculosis strain H37Rv PPD. Antigens
were prepared from M. tuberculosis strain H37Rv.
Culture filtrate proteins were isolated from 14-day mid-log-phase
cultures by filtration and concentration as described previously
(29), and LAM was removed by partitioning with Triton
X-114 (17). The LMWCFP was obtained by passing the sterile
culture supernatant over a 10,000-molecular-weight cutoff membrane
using an Amicon Beverly, Mass.) apparatus. The effluent (less than
10,000 Da) was collected. This material was concentrated using an
Amicon apparatus with a 1,000-molecular-weight cutoff membrane. The
concentrate was dialyzed against 10 mM ammonium bicarbonate, and the
protein concentration was determined using the bicinchoninic acid (BCA) method (27). The SCWP and cytosol fractions were prepared
as previously described (14, 18). The PPD preparation was
produced following a standard protocol (25). Protein
concentrations were determined by BCA assay (Pierce, Rockford, Ill.).
The optimal cell culture subfraction concentrations determined by
assaying multiple dilutions were 5 µg/ml for LMWCFP, 5 µg/ml for
CFP-LAM, 1 µg/ml for SCWP, 5 µg/ml for CYT, and 10 µg/ml for
H37Rv PPD.
IFN-
EIA.
The EIA was generally performed according to
the manufacturer's specifications. Briefly, 96-well plates precoated
with an anti-IFN-
monoclonal antibody were purchased. Each well was
filled with 50 µl of anti-human IFN-
-horseradish peroxidase
conjugate and 50 µl of the test specimen. The plate contents were
thoroughly mixed and incubated for 1 h at room temperature. The
plates were washed for 6 cycles with 300 µl of wash buffer. A
100-µl portion of substrate was added to each well. The admixture was
allowed to develop for 30 min (room temperature), at which time 50 µl of enzyme-stopping solution (1 N H2SO4) was
added to halt the reaction. Absorbance was measured at 450 nm using a
Molecular Devices (Sunnyvale, Calif.) plate reader.
A standard curve was generated by plotting the
A450 from four known samples (provided with the
Q-IFN kit) against their respective results in international units per
milliliter. The IFN-
values (in international units per milliliter
of the unknown samples were determined from the standard curve. We
developed our standard curve from the known replicates with a
point-to-point methodology rather than the manufacturer's suggested
linear best fit. This is described in more detail below. Tuberculin or
M. avium complex (MAC) classifications were determined by
calculating the following variables and using the criteria as outlined
by the manufacturer;
|
(1)
|
|
(2)
|
|
(3)
|
M. tuberculosis infection was defined as a
percent HuPPD of >15% and a percent avium difference of >
10%. MAC
infection was defined as a percent AvPPD of >20% and a percent avium
difference of <
10%.
The percent in vitro response to the M. tuberculosis
subfractions was calculated by normalizing the antigen-specific IFN-
production to the mitogen response and calculating the following for
each subfraction:
|
(4)
|
Curve fitting.
A linear fit through the standards is the
manufacturer's recommended methodology for generating the EIA standard
curve. The Q-IFN kit instructions imply the use of the entire curve
without a lower limit cutoff. This often yielded large negative values (in international units per milliliter) for the plasma blank due to
extrapolation at lower absorbance readings. The negative values affected the clinical interpretation rendered by the results of equations 1 to 4. Additionally, negative values for diluted samples could not be appropriately adjusted. Therefore, we chose to place our
zero standard at the origin and draw the curve from one known replicate
to the next (point to point). The values (in international units per
milliliter for the unknown samples were determined using the linear
portion between two known absorbance values (Microsoft Excel Trend
function). The point-to-point curve not only eliminated the negative
values but also compensated for any nonlinearity that may have existed
in the standards. The two methodologies for generating the standard
curve were evaluated with samples containing known quantities of
IFN-
. The point-to-point technique resulted in a more accurate
result for determining the actual quantity of IFN-
contained in the
sample and yielded a 0-IU/ml measurement for the blank (see Table 1).
As seen in Table 1, the absolute
difference between the two methods may not appear to be large; however,
the impact of the negative numbers on M. tuberculosis
classifications was not insignificant. Also, since a negative IFN-
value is not a biologic reality, we preferred to consider the blanks to
be zero (or greater than zero if some background IFN-
was observed).
The final tuberculin reactivity classifications were determined using
both methodologies, and the results were discordant (data not shown).
We utilized the point-to-point technique throughout this study because
it appears to be more accurate for determining IFN-
levels while
reflecting true biologic reactivity.
View this table:
[in this window]
[in a new window]
|
TABLE 1.
Comparison of calculated amounts of IFN- using
the Q-IFN ELISA with two different methods of standard curve
development
|
|
Statistics.
Agreement between the PPD-ST and the Q-IFN assay
was examined using Cohen's kappa. Kappa values of <0.4, 0.4 to 0.75, and >0.75 are consistent with poor, good, and excellent agreement, respectively (11). The association between the mean skin
test size (mean diameter of two axes' induration) and the in vitro IFN-
response (in international units per milliliter) (IU/ml) was
examined using Spearman's rank correlation coefficient
(rs). The in vitro percent subfraction responses
to the tuberculin-specific subfractions for the PPD-ST-positive and
-negative groups were compared using the Mann-Whitney rank sum test.
Receiver operating characteristic (ROC) curves were generated for the
subfractions which demonstrated a statistically significant difference
in response between the two skin test groups. Cutoff points for
interpreting in vitro tuberculin positivity and negativity, using
tuberculin-specific subfraction stimulants, were determined from the ROCs.
 |
RESULTS |
Clinical classification using PPD.
Sixteen of 20 PPD-ST-positive individuals were classified as tuberculin reactors with
the Q-IFN kit. Of the remaining four subjects, three were in vitro
negative for tuberculosis and one met criteria for MAC. Sixteen of 20 PPD-ST-negative participants were in vitro negative (negative for
M. tuberculosis as determined by the Q-IFN kit) for
tuberculosis. Of the remaining four skin test-negative subjects, two
were tuberculin reactive and two were MAC reactive. The agreement
between the PPD-ST and the Q-IFN assay was very good, with a Cohen's
kappa of 0.73. The eight Prior-POS patients were all classified as
tuberculin positive with the Q-IFN kit (Table
2). The median percent HuPPD response for
the PPD-POS subjects was 56.5%, compared to 7.9% for the control
group.
View this table:
[in this window]
[in a new window]
|
TABLE 2.
Agreement between the in vitro measurement of IFN-
with PPD stimulation using the Q-IFN kit and PPD-ST induration
|
|
Induration versus IFN-
values.
No statistically significant
correlation was found between the mean skin test induration (as defined
above) and the IFN-
values of PPD reactors. The PPD reactors had
skin test indurations ranging from 15 to 71 mm. The median value of
their IFN-
responses was 56.5 IU/ml, with an interquartile range of
50.2 IU/ml. Spearman's correlation coefficient for this comparison was
0.034, which denotes poor agreement (P = 0.887) (see
Fig. 1).
Purified M. tuberculosis antigens.
Using equation
4 above (percent subfraction response) to calculate IFN-
response as
a percentage of mitogen response, the mean levels with LMWCFP,
CFP-LAM, CYT, and H37Rv PPD were much higher in the
PPD-ST-positive group than the PPD-ST-negative group (see Table
3). These four subfractions were able to
discriminate between the two skin test groups using the following
cutoffs: 8% for LMWCFP, 16% for CFP-LAM, 8% for CYT, and 2% for
H37RvPPD (Fig. 2 to
5).
For these fractions the agreement (kappa coefficient) with
the skin test was 0.45, 0.35, 0.55, and 0.6, respectively. Although the
median percent SCWP responses with 1 µg/ml differed between the two
skin test groups (8.7 versus 22.8%), the overlap in ranges resulted in
no statistical difference (P = 0.076).
View this table:
[in this window]
[in a new window]
|
TABLE 3.
Agreement between the in vitro measurement of IFN-
with M. tuberculosis subfraction stimulation using
the Q-IFN kit and PPD-ST induration
|
|

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 2.
Comparison of the IFN- response to stimulation by
LMWCFP in the two PPD-ST groups. The subfraction IFN- response
is shown as a percentage of the mitogen response.
|
|

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 3.
Comparison of the IFN- response to stimulation by
CFP-LAM in the two PPD-ST groups. The subfraction IFN- response is
shown as a percentage of the mitogen response.
|
|

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 4.
Comparison of the IFN- response to stimulation by CYT
in the two PPD-ST groups. The subfraction IFN- response is shown as
a percentage of the mitogen response.
|
|

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 5.
Comparison of the IFN- response to stimulation by
H37Rv strain PPD in the two PPD-ST groups. The subfraction
IFN- response is shown as a percentage of the mitogen response.
|
|
 |
DISCUSSION |
The increase in prevalence of tuberculosis and the emergence of
multidrug-resistant strains have created a public health urgency for
early identification of M. tuberculosis-infected
individuals. The gold standard for detecting exposure remains the
Mantoux test, which was developed in the late 1800s and is one of the
oldest tests still in clinical use. Despite the long history of
clinical application, limitations and controversy with regard to
placement and interpretation remain. The PPD-ST has several drawbacks:
false-positive reactivity due to nontuberculin strains such as BCG,
interobserver variability in reading, false-negative results due to
underlying immunosuppression, and variability with repeat testing.
Controversies regarding interpretation continue to surface, partly
due to changes in the population being tested. Due to changes in
disease prevalence and demographics, a heightened need for early
detection and better testing methodologies has emerged. Most
research has tended toward developing better testing antigens and a
diagnostic assay system that would overcome the limitations of the
intradermal PPD-ST. In Australia a whole-blood culture kit based on
IFN-
production has recently been approved for in vitro human
tuberculosis screening. This kit has not been widely used to date and
is currently not approved in the United States. Our study has confirmed
the utility of the kit for in vitro PPD testing and has evaluated
tuberculin-specific subfractions in lieu of PPD in hopes of finding a
more accurate tuberculosis diagnostic system.
The human whole-blood culture assay evolved from earlier bovine studies
which compared traditional PBMC stimulation and skin testing to the new
whole blood assay. These studies demonstrated that the IFN-
test had
greater diagnostic sensitivity, cost less, and yielded rapid results
for cattle tuberculosis screening (24, 31, 32). This
concept was extended for human tuberculosis testing by Streeton et al.,
who reported a sensitivity and specificity of 90.5 and 98%,
respectively, for diagnosing M. tuberculosis exposure using
the Q-IFN kit (30). In their study the gold standard for
diagnosis was the PPD-ST and the study subjects were stratified according to their skin test induration and risk of exposure to tuberculosis. Converse et al. (4) and Kimura et al.
(16) used the Q-IFN in studies comparing the IFN release
assay with PPD-ST in populations at risk for M. tuberculosis
exposure (intravenous drug users with or without human immunodeficiency
virus [HIV] infection). They found that the Q-IFN assay detected more
reactors than the PPD-ST. Agreement between the two tests was weak
(4, 16). In our study of 40 patients there was good
agreement between the PPD-ST and the Q-IFN kit (kappa = 0.73). We
chose only to evaluate the agreement between the in vivo and in vitro
tests and not to refer to sensitivity and specificity because the
latter assume comparison to an adequate gold standard, which is
currently lacking.
One of the benefits of the in vitro system is the ability to use avian
PPD as a stimulant in order to differentiate MAC from tuberculosis
infection. We had three individuals test positive for MAC. Davidson et
al. evaluated a whole-blood culture system for non-M.
tuberculosis adenitis and reported a significant association between IFN-
response and MAC disease (7). We cannot be
certain if the MAC-positive individuals in our study actually carried MAC, since the patients were all healthy. A larger study with a group
of pulmonary MAC patients needs to be performed in order to address the
positive predictive value for differentiating MAC from M. tuberculosis. Eight patients with previous positive histories of
skin test reactivity who were now PPD-ST negative (Prior-POS) were all
classified as M. tuberculosis reactive by the Q-IFN kit. In
the literature the rate of reversion of the PPD-ST has been estimated
at 8% per year (21). This poses an additional limitation on skin testing, as the intradermal response appears to modulate over
time. Our eight patients were too small a group to draw any statistically significant conclusions regarding the in vitro response over time, but the results suggest that an individual once exposed may
continue to produce IFN-
upon antigen stimulation.
The immune response to tuberculosis is primarily cell mediated and is
an interplay between a variety of T cells, macrophages, and cytokines.
Historically, the host immune response to tuberculosis in humans has
been measured by the DTH skin test. Sepkowitz reported that the size of
the PPD-ST correlated with the risk of developing active tuberculosis
(26). The potent responders demonstrated a higher
incidence of developing active disease. Pottumarthy et al. showed a
correlation between IFN-
measured by the Q-IFN kit and PPD-ST
induration (23). Like Sepkowitz, these authors raised the
question whether quantifying the IFN-
response may predict the
future risk of developing disease. In our study we did not see a
correlation between IFN-
and size of skin test induration. The
discordance between these results is not unexpected since natural host
variability in whole blood culture response due to differing assay
conditions (time of sampling, time of incubation) may result in
quantitative differences in measurement of the same immunologic
mediator (8).
One significant drawback of both the PPD-ST and the Q-IFN kit is the
nonspecific response to PPD because of cross-reactivity between
tuberculin and other mycobacterial species. False positivity in the
M. tuberculosis skin testing due to BCG vaccination is well
documented. However, the in vitro IFN-
production of patients who
have received BCG may also be affected by cross-reacting mycobacterial antigens in the PPD preparation. Streeton et al. included BCG vaccinees
in their study but were unable to discern the effects of BCG on assay
results (30). Therefore, additional studies are needed to
delineate the diagnostic value of the Q-IFN kit in this population. The
in vitro diagnostic system affords a distinct advantage over the PPD-ST
in that one can test tuberculin-specific proteins without unnecessarily
exposing the patient. Low-molecular-weight antigens such as ESAT-6 have
been shown to differentiate between M. tuberculosis and BCG
strains of mycobacteria and thus ESAT-6 may serve as an additional
stimulant to determine the effect of BCG. Recently, ESAT-6 (6 kDa) was
evaluated in the Q-IFN assay and found to differentiate those infected
with tuberculosis from controls with high sensitivity and specificity
(15).
LMWCFP contains secreted proteins of less than 10,000 Da. Earlier work
with PBMC culture showed the stimulating capacity of proteins in this
subfraction (3, 22). We noted higher IFN-
production in
response to LMWCFP in the PPD-POS subjects using the whole-blood assay.
This likely represented reactivity not only to ESAT-6 epitopes but also
to the other low-molecular-weight proteins. The whole CFP-LAM
subfraction contains the majority of secreted proteins, most of which
are in the 10,000- to 100,000-Da range. Numerous purified proteins in
this subfraction have been evaluated as possible antigens for T-cell
stimulation. Boesen et al. showed strong IFN-
release in patients
with active minimal tuberculosis after PBMC stimulation with
molecular-mass fractions of CFP (2). Similar results were
obtained by Havlir and colleagues, who noted blastogenic activity with
the 30-, 37-, 44-, 57-, 64-, and 71-kDa proteins (12). Our
data, obtained using a whole-blood assay, show a significantly higher
IFN-
response in PPD reactors than in controls and are consistent
with these other studies, which assessed either lymphocyte
proliferation or cytokine release in PBMC culture supernatants.
The mycobacterial cell wall is a complex mixture of proteins,
carbohydrates, and phospholipids. The SCWP is an extremely
heterogeneous mixture of proteins, including low levels of LAM (~10
ng/ml). The nonspecific response noted in our study in both the
PPD-positive and -negative groups is best explained by the impurity of
the subfraction. Although specific stimulators are contained in this subfraction, as evident by work performed by Barnes et al., who demonstrated T-cell responses to 10-, 23-, 28-, and 30-kDa proteins, the contribution to the immune response from other uncharacterized protein fragments remains undefined (1). The heterogeneity of our subfraction compared to the purity of the Barnes mixture may
explain the discordant results between the two studies.
The cytosolic fraction is similar to the culture filtrate in that some
of the cytosolic proteins are released into culture. The CFP can
demonstrate considerable variability depending upon temperature and
harvesting time. In this study our CFP was late-log-phase culture, and
thus there may have been considerable redundancy between the CFP and
CYT. This may explain the similar specific IFN-
responses for these
two subfractions.
The discordance in results between the PPD supplied with the Q-IFN kit
and H37Rv in terms of degree of IFN-
response
demonstrates the heterogeneity in PPD preparations. The commercial
preparations are all standardized to a reference and labeled according
to their ability to produce a certain size induration with skin testing (labeling in TU). They are not standardized based on protein
concentration. Therefore, different preparations may have variable
protein distributions and may result in different in vitro stimulation
patterns. We used the H37Rv PPD at 10 µg/ml based on
preliminary dose-response studies. We do not know if this is equivalent
to the concentration of PPD in the Q-IFN kit, because the latter is
proprietary information. This may also explain the differential
response between the two PPD preparations.
These data demonstrate the efficacy of tuberculin-specific subfraction
preparations in stimulating IFN-
production in whole-blood culture.
However, none of the subfractions performed any better than the whole
PPD supplied with the Q-IFN kit. The PPD and the crude preparations
used in this study do not differentiate M. tuberculosis-specific responses from non-tuberculin-specific
responses. A concurrent test for MAC using AvPPD must be done. Those
subfractions demonstrating efficacy in this study should be further
isolated and studied in the whole-blood system. The immune response to tuberculosis is complex and is directed to a heterogenous mixture of
antigens rather than any one protein. Therefore, a cocktail of native
or recombinant antigens may prove to be more specific and sensitive in
diagnosing tuberculosis than any one immunodominant protein.
In conclusion, this study is the first to present the stimulating
potential of four M. tuberculosis subfractions (LMWCFP, CFP-LAM, SCWP, and CYT) in the Q-IFN kit. This information may prove
useful as the quest for a more specific M. tuberculosis testing antigen continues. Additionally, we provide new information regarding the behavior of different PPD formulations in culture, highlighting the importance of using one standardized preparation. Our
paper not only corroborates the previously published data confirming
the usefulness of Q-IFN as an in vitro test but also critically
evaluates the mechanics of the Q-IFN assay and raises several questions
regarding data reduction. The advantages of the blood test include the
absence of any reading or placement variability and the need for only
one office visit. The current disadvantages are the need for more
stringent laboratory requirements dealing with blood handling, cell
culture, and enzyme-linked immunosorbent assay (ELISA) testing. The
areas needing clarification include defining the performance
characteristics and the lower-limit cutoff for the EIA. Data are needed
on temporal measurements to determine if the time of day or different
days have any impact on the whole-blood stimulation response. Also, it
is not clear if the interval between the blood draw and processing has
any impact on the IFN-
response. Finally, the percent HuPPD cutoff
of 15% needs to be verified based on prevalence of disease in
different populations, as has been done with the PPD-ST. These issues
should be addressed and followed by large-scale trials to assess the
true sensitivity, specificity, and positive predictive value of the
Q-IFN kit, prior to its widespread use for clinical M. tuberculosis testing.
| 1.
|
Barnes, P.,
V. Mehra,
G. Hirschfield,
S. Fong,
C. Abou-Zeid,
G. Rook,
S. Hunter,
P. J. Brennan, and R. L. Modlin.
1989.
Characterization of T cell antigens associated with the cell wall protein-peptidoglycan complex of Mycobacterium tuberculosis.
J. Immunol.
143:2656-2662[Abstract].
|
| 2.
|
Boesen, H.,
B. Jensen,
T. Wilcke, and P. Andersen.
1995.
Human T-cell responses to secreted antigen fractions of Mycobacterium tuberculosis.
Infect. Immun.
63:1491-1497[Abstract].
|
| 3.
|
Coler, R. N.,
Y. A. Skeiky,
T. Vedvick,
T. Bement, et al.
1998.
Molecular cloning and immunologic reactivity of a novel low molecular mass antigen of Mycobacterium tuberculosis.
J. Immunol.
161:2356-2364[Abstract/Free Full Text].
|
| 4.
|
Converse, P. J.,
S. L. Jones,
J. Astemborski,
D. Vlahov, and N. M. Graham.
1997.
Comparison of a tuberculin interferon-gamma assay with the tuberculin skin test in high-risk adults: effect of human immunodeficiency virus infection.
J. Infect. Dis.
176:144-150[Medline].
|
| 5.
|
Daniel, T.
1980.
The immunology of tuberculosis.
Clin. Chest Med.
1:189-201[Medline].
|
| 6.
|
Daniel, T. M., and J. J. Ellner.
1993.
Immunology of tuberculosis, p. 75-101.
In
L. Reichman, and E. S. Hershfield (ed.), Tuberculosis: a comprehensive international approach, 1st ed. Marcel Dekker, Inc, New York, N.Y.
|
| 7.
|
Davidson, P. M.,
L. Creati,
P. R. Wood,
D. M. Robertson, and C. S. Hosking.
1993.
Lymphocyte production of gamma-interferon as a test for non-tuberculous mycobacterial lymphadenitis in children.
Eur. J. Pediatr.
152:31-35[CrossRef][Medline].
|
| 8.
|
De Groote, D.,
P. F. Zangerle,
Y. Gevaert,
M. F. Fassotte,
Y. Beguin,
J. Noizat-Pirenne,
R. Gathy,
M. Lopez,
I. Dehart, et al.
1992.
Direct stimulation of cytokines (IL-1 , TNF- , IL-6, IL_2, IFN- and GM-CSF) in whole blood. I. Comparison with isolated PBMC stimulation.
Cytokine
4:239-248[CrossRef][Medline].
|
| 9.
|
Fenton, M.,
M. Vermeulen,
S. Kim,
M. Burdick,
R. Strieter, and H. Kornfeld.
1997.
Induction of gamma interferon production in human alveolar macrophages by Mycobacterium tuberculosis.
Infect. Immun.
65:5149-5156[Abstract].
|
| 10.
|
Fleiss, J. L.
1981.
Statistical methods for rates and proportions, p. 218.
John Wiley & Sons, New York, N.Y.
|
| 11.
|
Francis, J.,
R. J. Seiler,
I. W. Wilkie,
D. O'Boyle, et al.
1978.
The sensitivity and specificity of various tuberculin tests using bovine PPD and other tuberculins.
Vet. Rec.
103:420-425[Medline].
|
| 12.
|
Havlir, D.,
R. S. Wallis,
H. Boom,
T. Daniel,
K. Chervenak, and J. Ellner.
1991.
Human immune response to Mycobacterium tuberculosis antigens.
Infect. Immun.
59:665-670[Abstract/Free Full Text].
|
| 13.
|
Heisser, A.,
R. DeGuzman,
J. Brooks,
N. Veltri,
V. Carregal,
L. S. Smith,
G. B. Carpenter, and R. J. M. Engler.
1996.
Delayed-type hypersensitivity testing for the evaluation of cellular immunity: normal responses for adult men and women.
J. Allergy Clin. Immunol.
97(1, part 3):399.
|
| 14.
|
Hirschfield, G. R.,
M. McNeil, and P. J. Brennan.
1990.
Peptidoglycan-associated polypeptides of Mycobacterium tuberculosis.
J. Bacteriol.
172:1005-1013[Abstract/Free Full Text].
|
| 15.
|
Johnson, P. D. R.,
R. L. Stuart,
M. L. Grayson,
D. Olden,
A. Clancy,
P. Ravn,
P. Andersen,
W. J. Britton, and J. S. Rothel.
1999.
Tuberculin-purified protein derivative, MPT-64, and ESAT-6 stimulated gamma interferon responses in medical students before and after Mycobacterium bovis BCG vaccination and in patients with tuberculosis.
Clin. Diagn. Lab. Immun.
6:934-937[Abstract/Free Full Text].
|
| 16.
|
Kimura, M.,
P. J. Converse,
J. Astemborski,
J. S. Rothel,
D. Vlahov,
G. W. Comstock,
N. M. Graham,
R. E. Chaisson, and W. R. Bishai.
1999.
Comparison between a whole blood interferon-gamma release assay and tuberculin skin testing for the detection of tuberculosis infection among patients at risk for tuberculosis exposure.
J. Infect. Dis.
179:1297-1300[CrossRef][Medline].
|
| 17.
|
Laal, S.,
K. M. Samanich,
M. G. Sonnenberg,
S. Zolla-Pazner,
J. M. Phadtare, and J. T. Belisle.
1997.
Human humoral responses to antigens of Mycobacterium tuberculosis: immunodominance of high-molecular-mass antigens.
Clin. Diagn. Lab. Immunol.
4:49-56[Abstract].
|
| 18.
|
Lee, B. Y.,
S. A. Hefta, and P. J. Brennan.
1992.
Characterization of the major membrane protein of virulent Mycobacterium tuberculosis.
Infect. Immun.
60:2066-2074[Abstract/Free Full Text].
|
| 19.
|
Lein, D., and F. Von Reyn.
1997.
In vitro cellular and cytokine responses to mycobacterial antigens: application to diagnosis of tuberculosis infection and assessment of response to mycobacterial vaccines.
Am. J. Med. Sci.
313:364-371[CrossRef][Medline].
|
| 20.
|
Mantoux, C.
1910.
L'intradermo-reaction a la tuberculin et son interpretation clinique.
Presse Med.
18:10-13.
|
| 21.
|
Menzies, D.
1999.
Interpretation of repeated tuberculin tests, boosting, conversion and reversion.
Am. J. Respir. Crit. Care Med.
159:15-21[Free Full Text].
|
| 22.
|
Pais, T. F.,
R. A. Silv,
B. Smedegaard,
R. Appelberg, and P. Andersen.
1998.
Analysis of T cells recruited during delayed-type hypersensitivity to purified protein derivative versus challenge with tuberculosis infection.
Immunology
95:69-75[CrossRef][Medline].
|
| 23.
|
Pottumarthy, S.,
A. Morris,
A. Harrison, and V. Wells.
1999.
Evaluation of the tuberculin gamma interferon assay: potential to replace the Mantoux skin test.
J. Clin. Microbiol.
37:3229-3232[Abstract/Free Full Text].
|
| 24.
|
Rothel, J. S.,
S. L. Jones,
L. A. Corner,
J. C. Cox, and P. R. Wood.
1992.
The gamma-interferon assay for diagnosis of bovine tuberculosis in cattle: conditions affecting the production of gamma-interferon in whole blood culture.
Aust. Vet. J.
69:1-4[Medline].
|
| 25.
|
Seibert, F. B., and J. T. Glenn.
1941.
Tuberculin purified protein derivative: preparation and analysis of a large quantity for standard.
Am. Rev. Tuber.
44:9-25.
|
| 26.
|
Sepkowitz, K. A.
1996.
Tuberculin skin testing and the health care worker: lessons of the Prophit Survey.
Tuber. Lung Dis.
77:81-85[CrossRef][Medline].
|
| 27.
|
Smith, P. K.,
R. I. Krohn,
G. T. Hermanson,
A. K. Mallia,
F. H. Gartner,
M. D. Provenzano,
E. K. Fujimoto,
N. M. Goeke,
B. J. Olson, and D. C. Klenk.
1985.
Measurement of protein using bicinchoninic acid.
Anal. Biochem.
150:76-85[CrossRef][Medline].
|
| 28.
|
Snider, D.
1982.
The tuberculin skin test.
Am. Rev. Respir. Dis.
125(Suppl.):108-118[Medline].
|
| 29.
|
Sonnenberg, M. G., and J. T. Belisle.
1997.
Definition of Mycobacterium tuberculosis culture filtrate proteins by two-dimensional polyacrylamide gel electrophoresis, N-terminal amino acid sequencing, and electrospray mass spectrometry.
Infect. Immun.
65:4515-4524[Abstract].
|
| 30.
|
Streeton, J. A.,
N. Desem, and S. L. Jones.
1998.
Sensitivity and specificity of a gamma interferon blood test for tuberculosis infection.
Int. J. Tuberc. Lung Dis.
2:443-450[Medline].
|
| 31.
|
Wood, P. R.,
L. A. Corner,
J. S. Rothel, et al.
1991.
Field comparison of the interferon-gamma assay and the intradermal tuberculin test for the diagnosis of bovine tuberculosis.
Aust. Vet. J.
68:286-290[Medline].
|
| 32.
|
Wood, P. R., and J. S. Rothel.
1994.
In vitro immunodiagnostic assay for bovine tuberculosis.
Vet. Microbiol.
40:125-135[CrossRef][Medline].
|